Six models of a new insulin pen (MADI): Description and first clinical trial

Abstract

Six models of a new type of insulin pen (MADI) were developed comprising models for insulin U‐40, U‐80 and U‐100 with a single dose of either one or two units of insulin in each of them1−4. Every model may be easily adapted to be used either as a ‘needle pen’ or a ‘catheter pen’. In the needle pen, a sliding cover prevents the contamination of the needle. A syringe‐like interchangeable plastic reservoir (3ml) is filled (and can be refilled up to 100 times) by the patient from the insulin vials, with any kind of soluble insulin. Actual insulin administration occurs by twisting the cap. A clinical trial with 365 adult patients and 46 children (1991‐93) showed good patient satisfaction in 95%. There were 17 MADI pen failures requiring technical assistance in the 12 months of the clinical trial. The preference for a catheter pen was assessed separately in a group of 35 carefully‐trained patients. There was a marginal preference for the needle pen (54% of the patient days) compared with the catheter pen (46% of the patient days). In 345 patients without special training, the catheter pen was only preferred by one patient (0.3%). MADI pen may be recommended as an insulin delivery device of choice. In particular, patients on any form of animal insulin and/or U‐40 and/or U‐80 insulin may benefit from this pen.

Occurence of Adverse Events Due to Continuous Glucose Monitoring

“…is a key point in medical care. At the Faculty of Medicine, Palacký University, Olomouc, Czech Republic, attention was payed to the practical use of recent methods of insulin administration 22 . Thorough investigations of potential hazards due to re-use of disposable needles have been done in persons with type 1 diabetes mellitus 23 .…”

Intensive Management of Type 1 Diabetes in Adults: One Centre Experience 1970–2022

“…No metabolic differences were seen when using the MADI 7/2ml needle pen (Figure 14) or catheter pen [78,106]. The needle pen was preferred in 54 % of all patient days.…”

“…This chapter is focused on selected clinical trials and routine management of people with type 1 diabetes (PWD1) carried out since the year 1970 at the Teaching Hospital and Palacký University Olomouc [55,56], mostly in cooperation with experts from diabetes centres in the Czech and Slovak Republics [57], Institute of Diabetes G. Katsch Karlsburg [58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76], Heinrich Heine Universität Düsseldorf [77], Royal Infirmary Edinburgh [62] and St. Thomas Hospital London [62,78].…”

Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020

“…[30,31] Six models of a new type of MADI for insulin U-40, U-80 and U-100 were developed. [32] (Figure 2) In the needle pen (Figure 3) a sliding cover prevents the contamination of the needle which remains invisible in the course of injection and might be reused without sterilization. [33] In the catheter pen ( Figure 4) the catheter remained inserted in subcutaneous tissue for 3 days.…”